Dr. Cynthia Gagnon Receives 2024 Steinert Award, IDMC-15 Meeting to Take Place in Saguenay
We are pleased to share that NMD4C steering committee member Dr. Cynthia Gagnon was honoured with a Steinert Clinical Sciences Award at the recent International Myotonic Dystrophy Consortium Meeting (IDMC-14) in Nijmegen, Netherlands!
The prestigious Steinert awards are presented to individuals who display excellence in clinical and basic research on myotonic dystrophy. Based in Québec’s Saguenay-Lac-Saint-Jean region, an area with an elevated prevalence of Myotonic dystrophy (DM1) where 1:600 people are affected by the disease, Dr. Gagnon is the scientific director of the Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN) where she leads research projects and clinical trials on a variety of NMDs, including DM1. Dr. Gagnon has established an internationally renowned research program focused on documenting the natural history of NMDs through an interdisciplinary perspective to document disease progression and identify significant predictor and explanatory factors related to participation in daily activities and social roles of patients, and defining the best outcome measures to assess potential therapeutic targets. Dr. Gagnon is a key figure in growing the number of clinical trials available in Canada for DM1, facilitating trials at sites in Saguenay-Lac-Saint-Jean and collaborating with Dr. Hanns Lochmüller’s research team in Ottawa.
Saguenay Prepares to Welcome International Colleagues to IDMC-15 in 2026
Dr. Gagnon and GRIMN will host the 15th edition of the IDMC in Saguenay, QC in the fall of 2026.
We look forward to welcoming the leading international myotonic dystrophy conference to Canada, and will share further news on the meeting as details are available.
Read next...
Spinal Muscular Atrophy Outcome Measures Workshop (English Language)
The NMD4C will be hosting an English-language interactive training workshop on standardizing assessment practices in SMA outcome measures.
NMD4C Launch Survey to Assess Familiarity and Experience in Outcome Measures in NMDs
As we anticipate novel treatments for other neuromuscular conditions, we would like to understand your familiarity and experience with the outcome measures in clinical trials underway or for treatments for NMDs approved in other jurisdictions through a short survey.
NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards
We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.
NMD4C Launch Canadian Neuromuscular Clinical Trial Network
We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.
Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network
This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted.
MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants
Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.